J. Erfán

Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study

Lisa Licitra, Fernando Rivera, Éva Remenár et al. · Annals of Oncology · 2010 · 230 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Endovascular Thrombectomy for Large Ischemic Stroke Across Ischemic Injury and Penumbra Profiles

Amrou Sarraj, Ameer E Hassan, Michael Abraham et al. · JAMA · 2024 · 96 citations · Full text

Medicine, Neurological Surgery, Neurosurgery +17

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)

Jan B. Vermorken, Frédéric Peyrade, John C. Krauss et al. · Annals of Oncology · 2014 · 94 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)

Ágnes Ruzsa, Mehmet Şen, Mark D. Evans et al. · Investigational New Drugs · 2014 · 57 citations

Medicine, Oncology, Cancer Pharmacology +9

Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) (EXTREME)

J. B. Vermorken, M. E. Vega-Villegas, Éva Remenár et al. · Journal of Clinical Oncology · 2006 · 21 citations

Medicine, Oncology, Pharmacology +17